While numerous RCTs have shown that PD-1/PD-L1 inhibitors enhance the long-term prognosis of unresectable or metastatic GC and EC (41, 42), our findings reveal no significant differences in long-term prognostic outcomes, such as OS and PFS, for resectable locally advanced cases. This evidence concerns the gene CD274 and gastric cancer.